Phenylketonuria: Nutritional advances and challenges

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Giovannini, Marcello ^a   Verduci, Elvira ^a   Salvatici, Elisabetta ^a   Paci, Sabrina ^a   Riva, Enrica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

LCPUFA supplementation; LNAA; new strategies; PKU; sapropterin; treatment advances

Indexed keywords

AMINO ACID DERIVATIVE; DOCOSAHEXAENOIC ACID; FISH OIL; GLYCOPROTEIN; ICOSAPENTAENOIC ACID; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; SAPROPTERIN;

ADOLESCENCE; CHEESE; DIET; DIET THERAPY; DIETARY FIBER; HEALTH PROGRAM; HUMAN; INFANCY; MEAL; METABOLIC PARAMETERS; NUTRITIONAL PARAMETERS; PALATABILITY; PATIENT COMPLIANCE; PHENOTYPE; PHENYLKETONURIA; PROTEIN BLOOD LEVEL; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 84856430235     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-7     Document Type: Review

References (42)

1. The hyperphenylalaninemias. Scriver CR, Kaufman S, Eisensmith RC, Woo SLC, The metabolic and molecular bases of inherited disease McGraw-Hill, New York, Scriver CR, Beaudet AL, Sly WS, Valle D, 7 1995 1015 1075
2. Phenylketonuria. Blau N, van Spronsen FJ, Levy HL, Lancet 2010 376 1417 1427 10.1016/S0140-6736(10)60961-0 20971365
3. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeld K, Nowacka M, Robert M, van Rijn M, Eur J Clin Nutr 2011 65 275 278 10.1038/ejcn.2010.258 21119696
4. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: association with concurrent and lifetime phenylalanine concentrations. Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, Sergeant JA, Neuropsychologia 2002 40 7 15 10.1016/S0028-3932(01) 00078-1 11595258 (Pubitemid 32929971)
5. Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ, Eur J Pediatr 1996 155 Suppl 1 33 38 8828606
6. Behaviour and school achievement in patients with early and continuously treated phenylketonuria. Stemerdink BA, Kalverboer AF, van der Meere JJ, van der Molen MW, Huisman J, de Jong LW, Slijper FM, Verkerk PH, van Spronsen FJ, J Inherit Metab Dis 2000 23 548 562 10.1023/A:1005669610722 11032330
7. Breast feeding in IMD. Depondt E, Evans S, Daly A, Hendriksz C, Chakrapani AA, Saudubray JM, J Inherit Metab Dis 2006 29 299 303 10.1007/s10545-006-0332-x 16763891 (Pubitemid 43880624)
8. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA J 2010 8 1461
9. Apolipoprotein B gene polymorphism and plasma lipid levels in phenylketonuric children. Verduci E, Agostoni C, Biondi ML, Radaelli G, Giovannini M, Riva E, Prostaglandins Leukot Essent Fatty Acids 2004 71 117 120 10.1016/j.plefa.2003.12.022 15207528 (Pubitemid 38881250)
10. Polyunsaturated fatty acid status in patients with phenylketonuria. Sanjurjo P, Perteagudo L, Rodriguez Soriano J, Vilaseca A, J Inherit Metab Dis 17 1994 17 704 709 10.1007/BF00712012
11. Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. Galli C, Agostoni C, Mosconi C, Riva E, Salari PC, Giovannini M, J Pediatr 1991 119 562 567 10.1016/S0022- 3476(05)82405-9 1919887
12. Lipid status and fatty acid metabolism in phenylketonuria. Giovannini M, Biasucci G, Agostoni C, Luotti D, Riva E, J Inherit Metab Dis 1995 18 265 272 10.1007/BF00710414 7474891
13. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Burdge GC, Wootton SA, Br J Nutr 2002 88 411 420 10.1079/BJN2002689 12323090 (Pubitemid 35251957)
14. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, Demmelmair H, Illig T, Koletzko B, Heinrich J, Hum Mol Genet 15 2006 15 1745 1756 10.1093/hmg/ddl117 (Pubitemid 43821765)
15. World Association of Perinatal Medicine Dietary Guidelines Working Group, The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. Koletzko B, Lien E, Böhles H, Campoy C, Cetin I, Decsi T, Dudenhausen JW, Dupont C, Forsyth S, Hoesli I, Holzgreve W, Lapillonne A, Putet G, Secher NJ, Symonds M, Szajewska H, Willatts P, Uauy R, J Perinat Med 2008 36 5 14 10.1515/JPM.2008.001 18184094
16. Effect of diet on the fatty acid composition of major phospholipids of infant cerebral cortex. Farquharson J, Jamieson EC, Abbasi KA, Ainslie Patrick WJ, Logan RW, Cockburn F, Arch Dis Child 1995 72 198 203 10.1136/adc.72.3.198 7741563
17. Impaired arachidonic (20:4 n-6) and docosahexaenoic (22:6 n-3) acid synthesis by phenilalanine metabolites as etiological factors in the neuropathology of phenylketonuria. Infante JP, Huszagh VA, Mol Gen Metab 2001 72 185 198 10.1006/mgme.2001.3148 (Pubitemid 34171435)
18. Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations. Leuzzi V, Rinalduzzi S, Chiarotti F, Garzia P, Trasimeni G, Accornero N, J Inherit Metab Dis 1998 21 351 364 10.1023/A:1005346422918 9700592 (Pubitemid 28356417)
19. Behaviour in early treated phenylketonuria: a systematic review. Smith I, Knowles J, Eur J Pediatr 2000 159 Suppl 2 89 93 11043152
20. A randomised trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria. Agostoni C, Harvie A, McCulloch DL, Demellweek C, Cockburn F, Giovannini M, Murray G, Harkness RA, Riva E, Developmental Medicine & Child Neurology 2006 48 207 212 10.1017/S0012162206000442 22319595 (Pubitemid 44404267)
21. Effects of long-chain polyunsaturated fatty acid supplementation on fatty acid status and visual function in treated children with hyperphenylalaninemia. Agostoni C, Massetto N, Biasucci G, Rottoli A, Bonvissuto M, Bruzzese MG, Giovannini M, Riva E, J Pediatr 2000 137 504 509 10.1067/mpd.2000.108398 11035829
22. Long terms effects of long chain polyunsaturated fats in hyperphenylalaninemic children. Agostoni C, Verduci E, Massetto N, Fiori L, Radaelli G, Riva E, Giovannini M, Arch Dis Child 2003 88 582 583 10.1136/adc.88.7.582 12818902 (Pubitemid 36783036)
23. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Beblo S, Reinhardt H, Muntau AC, Mueller-Felber W, Roscher AA, Koletzko B, Neurology 2001 57 1488 1491 11673596 (Pubitemid 32995735)
24. Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. Beblo S, Reinhardt H, Demmelmair H, Muntau AC, Koletzko B, J Pediatr 2007 150 479 484 10.1016/j.jpeds.2006.12.011 17452220 (Pubitemid 46602320)
25. Omega-3 LC-PUFA supply and neurological outcomes in children with phenylketonuria (PKU). Koletzko B, Beblo S, Demmelmair H, Hanebutt FL, J Pediatr Gastroenterol Nutr 2009 48 Suppl 1 2 7 10.1097/MPG.0b013e3181977399 19214054
26. Nutritional issues in treating phenylketonuria. Feillet F, Agostoni C, J Inherit Metab Dis 2010 33 659 664 10.1007/s10545-010-9043-4 20151202
27. Purification and use of glycomacropeptide for nutritional management of phenylketonuria. Laclair CE, Ney DM, MacLeod EL, Etzel MR, J Food Sci 2009 74 199 206 10.1111/j.1750-3841.2009.01134.x 19490325
28. Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKU. Lim K, van Calcar SC, Nelson KL, Gleason ST, Ney DM, Mol Genet Metab 2007 92 176 178 10.1016/j.ymgme.2007.06.004 17644019 (Pubitemid 47361894)
29. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria. Ney DM, Hull AK, van Calcar SC, Liu X, Etzel MR, J Nutr 2008 138 316 322 18203898 (Pubitemid 351213646)
30. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Van Calcar SC, MacLeod EL, Gleason ST, Etzel MR, Clayton MK, Wolff JA, Ney DM, Am J Clin Nutr 2009 89 1068 1077 10.3945/ajcn.2008.27280 19244369
31. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria. MacLeod EL, Clayton MK, van Calcar SC, Ney DM, Mol Genet Metab 2010 100 303 308 10.1016/j.ymgme. 2010.04.003 20466571
32. Metabolism of amino acids and proteins. Christensen HN, Ann Rev Biochem 1953 22 235
33. Large neutral amino acids in the treatment of PKU: from theory to practice. Van Spronsen FJ, De Groot MJ, Hoeksma M, Reijngoud DJ, Van Rijn M, J Inherit Metab Dis 2010 33 671 676 10.1007/s10545-010-9216-1 20976625
34. Large neutral amino acids block phenylketonuria transport into brain tissue in patients with phenylketonuria. Pietz J, Kreis R, Rupp A, Mayatepek E, Cboesch D, Bremer HJ, J Clin Invest 1999 103 1169 1178 10.1172/JCI5017 10207169 (Pubitemid 29207251)
35. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Koch R, Moseley MD, Yano S, Nelson M, Moats RA, Mol Genet Metab 2003 79 110 113 10.1016/S1096-7192(03)00078-7 12809641 (Pubitemid 36693929)
36. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. Matalon R, Michals-Matalon K, Bhatia G, Burlina AB, Burlina AP, Braga C, Fiori L, Giovannini M, Grechanina E, Novikov P, Grady J, Tyring SK, Guttler F, J Inherit Metab Dis 2007 30 153 158 10.1007/s10545-007-0556-4 17334706 (Pubitemid 46487995)
37. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, Rae C, Green K, Wilcken B, Christodoulou J, Mol Genet Metab 2007 91 48 54 10.1016/j.ymgme.2007.02.002 17368065 (Pubitemid 46550929)
38. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Zurflüh MR, Zschocke J, Lindner M, Feillet F, Chery C, Burlina A, Stevens RC, Thöny B, Blau N, Hum Mutat 2008 29 167 175 10.1002/humu.20637 17935162
39. Advances and challenges in phenylketonuria. Harding CO, Blau N, J Inherit Metab Dis 2010 33 645 648 10.1007/s10545-010-9247-7 21086047
40. Adjusting diet with sapropterin in phenylketonuria: what factors should be considered? Macdonald A, Ahring K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, César Rocha J, Van Rijn M, Bélanger-Quintana A, Br J Nutr 2011 5 1 8
41. Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin. Gassiá R, Vilaseca MA, Lambruschini N, Boix C, Fusté ME, Campistol J, Mol Genet Metab 2010 99 75 78 20123475
42. Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria. Sarkissian CN, Kang TS, Gámez A, Scriver CR, Stevens RC, Mol Genet Metab 2011 104 249 254 10.1016/j.ymgme.2011.06.016 21803624